Immunoprecipitation/ Mass spectrometry assay (IPMS)
This work is in collaboration with the Antibody Characterization Laboratory and the National Cancer Institute’s Clinical Proteomic Technologies for Cancer (CPTC). One of the goals of CPTC is to provide well-characterized and validated monoclonal antibodies for the scientific community. IPMS will provide information about the ability of specific antibodies to immunoprecipitate their antigens. In addition the method will provide final identification of the antigen of interest immunoprecipitated from complex mixture (such as serum, cell lysate).